


# World Journal of *Stem Cells*

*World J Stem Cells* 2011 August 26; 3(8): 70-82



## Editorial Board

2009-2013

The *World Journal of Stem Cells* Editorial Board consists of 284 members, representing a team of worldwide experts in stem cells research. They are from 28 countries, including Australia (5), Austria (1), Belgium (3), Brazil (2), Canada (7), China (19), Czech Republic (2), Denmark (4), Finland (3), France (5), Germany (14), Hungary (3), India (3), Iran (1), Israel (4), Italy (13), Japan (18), Netherlands (4), Norway (2), Singapore (10), South Korea (15), Spain (6), Sweden (2), Switzerland (3), Turkey (2), United Arab Emirates (1), United Kingdom (15), and United States (117).

### PRESIDENT AND EDITOR-IN-CHIEF

Lian-Sheng Ma, *Beijing*

### STRATEGY ASSOCIATE EDITORS-IN-CHIEF

Philippe Bourin, *Toulouse*  
Andras Dinnyes, *Godollo*  
Umberto Galderisi, *Napoli*  
Mikhail G Kolonin, *Houston*  
Balazs Sarkadi, *Budapest*

### GUEST EDITORIAL BOARD MEMBERS

Ing-Ming Chiu, *Miaoli*  
Chie-Pein Chen, *Taipei*  
Ju Jyh-Cherng, *Taichung*  
Hossein Hosseinkhani, *Taipei*  
Steven Shoei-Lung Li, *Kasohsiung*  
Tzu-Hao Wang, *Tao-Yuan*

### MEMBERS OF THE EDITORIAL BOARD



#### Australia

Jeremy M Crook, *Melbourne*  
Alice Pébay, *Victoria*  
Kuldip S Sidhu, *Sydney*  
Ernst Wolvetang, *Brisbane*  
Xin-Fu Zhou, *Adelaide*



#### Austria

Ludwig Aigner, *Salzburg*



#### Belgium

Yves Beguin, *Liege*

Mieke Geens, *Brussels*  
Najimi Mustapha, *Brussels*



#### Brazil

Niels Olsen Saraiva Câmara, *São Paulo*  
Naiara Zoccal Saraiva, *Jaboticabal*



#### Canada

Borhane Annabi, *Montreal*  
Rosario Isasi, *Quebec*  
Xiao-Yan Jiang, *Vancouver*  
Seung U Kim, *Vancouver*  
Ren-Ke Li, *Toronto*  
Jeffrey A Medin, *Toronto*  
Kursad Turksen, *Ottawa*



#### China

Xiu-Wu Bian, *Chongqing*  
Yong Dai, *Shenzhen*  
Zhong-Chao Han, *Tianjin*  
Zhang Hao, *Beijing*  
Anskar YH Leung, *Hong Kong*  
Gang Li, *Hong Kong*  
Gui-Rong Li, *Hong Kong*  
Kai-Yan Liu, *Beijing*  
Yi-Jia Lou, *Hangzhou*  
Xue-Tao Pei, *Beijing*  
Jing-He Tan, *Tan-An*  
Jin-Fu Wang, *Hangzhou*  
Yun-Hai Zhang, *Hefei*



#### Czech Republic

Petr Dvorak, *Brno*  
Jaroslav Mokry, *Hradec Kralove*



#### Denmark

Basem M Abdallah, *Odense*  
Poul Maddox-Hyttel, *Frederiksberg*  
Lin Lin, *Tjele*  
Soren Paludan Sheikh, *Odense*



#### Finland

Jukka Partanen, *Helsinki*  
Petri Salven, *Helsinki*  
Heli Skottman, *Tampere*



#### France

Alain Chapel, *Paris*  
Gwendal Lazennec, *Montpellier*  
Muriel Perron, *Paris*  
Xavier Thomas, *Lyon*



#### Germany

James Adjaye, *Berlin*  
Christian Buske, *Ulm*  
Denis Corbeil, *Dresden*  
Frank Edenhofer, *Bonn*  
Ursula Margarethe Gehling, *Langen*  
Eric Gottwald, *Eggenstein-Leopoldshafen*  
Jorg Kleeff, *Munich*  
Gesine Kögler, *Düsseldorf*  
Nan Ma, *Rostock*  
Ulrich Martin, *Hannover*  
Heinrich Sauer, *Giessen*  
Richard Schäfer, *Tübingen*  
Sonja Schrepfer, *Hamburg*  
Wolfgang Wagner, *Aachen*

**Hungary**Ferenc Uher, *Budapest***India**Gurudutta U Gangenahalli, *Delhi*  
Asok Mukhopadhyay, *New Delhi*  
Anjali Suhas Shiras, *Maharashtra***Iran**Masoud Soleimani, *Tehran***Israel**Zeev Blumenfeld, *Haifa*  
Rachel Sarig, *Rehovot*  
Avichai Shimoni, *Tel-Hashomer*  
Shimon Slavin, *Tel Aviv***Italy**Carlo Alberto Beltrami, *Udine*  
Clotilde Castaldo, *Naples*  
Carmelo Carlo-Stella, *Milano*  
Massimo Dominici, *Modena*  
Stefania Filos, *Naples*  
Angela Gritti, *Milano*  
Roberta Morosetti, *Rome*  
Felicita Pedata, *Florence*  
Anna Chiara Piscaglia, *Rome*  
Stefano Pluchino, *Milan*  
Caterina AM La Porta, *Milan*  
Domenico Ribatti, *Bari***Japan**Tomoki Aoyama, *Kyoto*  
Susumu Ikehara, *Osaka*  
Taro Matsumoto, *Tokyo*  
Yuko Miyagoe-Suzuki, *Tokyo*  
Hiroyuki Miyoshi, *Tsukuba*  
Takashi Nagasawa, *Kyoto*  
Tetsuhiro Niidome, *Kyoto*  
Toshio Nikaido, *Toyama*  
Kohzo Nakayama, *Nagano*  
Tsukasa Ohmori, *Tochigi*  
Caterina AM La Porta, *Milan*  
Kumiko Saeiki, *Tokyo*  
Kazunobu Sawamoto, *Aichi*  
Mikiko C Siomi, *Tokyo*  
Yoshiaki Sonoda, *Osaka*  
Takashi Tada, *Kyoto*  
Kotaro Yoshimura, *Tokyo*  
Louis Yuge, *Hiroshima***Netherlands**Dirk Gijsbert de Rooij, *Amsterdam*Christine Mummery, *Leiden*  
Frank JT Staal, *Leiden*  
Marten Piet Smidt, *Utrecht***Norway**Brynjar Foss, *Stavanger*  
Berit Bølge Tysnes, *Bergen***Singapore**Yu Cai, *Research Link*  
Tong Cao, *Singapore*  
Jerry Chan, *Singapore*  
Gavin Stewart Dawe, *Medical Drive*  
Chan Kwok-Keung Ken, *Singapore*  
Chan Woon Khiong, *Singapore*  
Steve KW Oh, *Singapore*  
Seeram Ramakrishna, *Singapore*  
Herbert Schwarz, *Singapore*  
Shu Wang, *Biopolis Way***South Korea**Jong Wook Chang, *Seoul*  
Chong-Su Cho, *Seoul*  
Ssang-Goo Cho, *Seoul*  
Ho Jae Han, *Gwangju*  
Ki-Chul Hwang, *Seoul*  
Kyung-Sun Kang, *Seoul*  
Haekwon Kim, *Seoul*  
Hoeon Kim, *Daejeon*  
Mee Kum Kim, *Seoul*  
Yoon Jun Kim, *Seoul*  
Soo-Hong Lee, *Seoul*  
Dae-Sik Lim, *Daejeon*  
Byung Soon Park, *Seoul*  
Sun U Song, *Incheon*  
Seung Kwon You, *Seoul***Spain**Fernando Cobo, *Granada*  
Sabrina C Desbordes, *Barcelona*  
Marta Muñoz Llamosas, *España*  
Maria P De Miguel, *Madrid*  
María Dolores Miñana, *Valencia*  
Felipe Prosper, *Navarra***Sweden**M Quamrul Islam, *Linköping*  
Stefan Karlsson, *Lund***Switzerland**Thomas Daikeler, *Basel*  
Sabrina Mattoli, *Basel*  
Arnaud Scherberich, *Basel***Turkey**Alp CAN, *Ankara*  
Berna Arda, *Ankara***United Arab Emirates**Sherif M Karam, *Al-Ain***United Kingdom**Dominique Bonnet, *London*  
Kristin Mary Braun, *London*  
Wei Cui, *London*  
David C Hay, *Edinburgh*  
Wael Kafienah, *Bristol*  
Francis L Martin, *Lancaster*  
Mike Modo, *London*  
Donald Palmer, *London*  
Dame Julia Polak, *London*  
James Alexander Ross, *Edinburgh*  
Alastair James Sloan, *Cardiff*  
Virginie Sottile, *Nottingham*  
Hong Wan, *London*  
He-Ping Xu, *Aberdeen*  
Rike Zietlow, *Cardiff***United States**Gregor Barr Adams, *Los Angeles*  
Kinji Asahina, *Los Angeles*  
Craig S Atwood, *Madison*  
Debabrata Banerjee, *New Brunswick*  
Aline M Betancourt, *New Orleans*  
Surinder Kumar Batra, *Omaha*  
Bruce Alan Bunnell, *New Orleans*  
Jason A Burdick, *Philadelphia*  
Anthony WS Chan, *Atlanta*  
Rebecca J Chan, *Indianapolis*  
G Rasul Chaudhry, *Rochester*  
Jonathan Donald Chesnut, *Carlsbad*  
Herman S Cheung, *Coral Gables*  
Kent W Christopherson II, *Chicago*  
David Wade Clapp, *Indianapolis*  
Rubin Clinton, *New York*  
Claudius Conrad, *Boston*  
Charles Samuel Cox, *Houston*  
Marcos de Lima, *Houston*  
Douglas C Dean, *Louisville*  
Goberdhan Dimri, *Evanston*  
David Dingli, *Rochester*  
Fu-Liang Du, *Vernon*  
Todd Evans, *New York*  
Toshihiko Ezashi, *Columbia*  
Vincent Falanga, *Alternate*  
Ira J Fox, *Pittsburgh*  
Markus Frank, *Boston*  
Sanga Gehmert, *Houston*  
Yong-Jian Geng, *Houston*  
Joseph C Glorioso, *Pittsburgh*  
Kristbjorn Orri Gudmundsson, *Frederick*  
Yan-Lin Guo, *Hattiesburg*  
Tong-Chuan He, *Chicago*  
Lorraine Iacovitti, *Philadelphia*  
Kunlin Jin, *Novato*

Michael R King, *Ithaca*  
Uma Lakshminpathy, *Carlsbad*  
Hillard Michael Lazarus, *Shaker Heights*  
Techung Lee, *Buffalo*  
Robert C Miller, *Rochester*  
Tao-Sheng Li, *Los Angeles*  
Xiao-Nan Li, *Houston*  
Ching-Shwun Lin, *San Francisco*  
P Charles Lin, *Nashville*  
Su-Ling Liu, *Ann Arbor*  
Aurelio Lorico, *Las Vegas*  
Jean-Pierre Louboutin, *Philadelphia*  
Bing-Wei Lu, *Stanford*  
Qing Richard Lu, *Dallas*  
Nadya L Lumelsky, *Bethesda*  
Hong-Bo R Luo, *Boston*  
Hinh Ly, *Atlanta*  
Teng Ma, *Tallahassee*  
Kenneth Maiese, *Detroit*  
Robert L Mauck, *Philadelphia*  
Glenn Edwards Mcgee, *New York*  
Murielle Mimeault, *Omaha*  
Guo-Li Ming, *Baltimore*  
Masato Nakafuku, *Cincinnati*  
Christopher Niyibizi, *Hershey*  
Seh-Hoon Oh, *Gainesville*  
Frank Pajonk, *Los Angeles*

Gregory M Pastores, *New York*  
Derek A Persons, *Memphis*  
Donald G Phinney, *Florida*  
Donald George Phinney, *New Orleans*  
Dimitris G Placantonakis, *New York*  
George E Plopper, *Troy*  
Derek Radisky, *Jacksonville*  
Murugan Ramalingam, *Gaithersburg*  
Pranela Rameshwar, *Newark*  
Jeremy N Rich, *Cleveland*  
Angie Rizzino, *Omaha*  
Paul Ronald Sanberg, *Tampa*  
Gerald Phillip Schatten, *Pittsburgh*  
Ashok Kumar Shetty, *Durham*  
Igor I Slukvin, *Madison*  
Shay Soker, *Winston-Salem*  
Hong-Jun Song, *Baltimore*  
Kenichi Tamama, *Columbus*  
Dean G Tang, *Smithville*  
Hugh S Taylor, *New Haven*  
Jonathan L Tilly, *Boston*  
Jakub Tolar, *Minneapolis*  
Deryl Troyer, *Manhattan*  
Scheffer Chuei-Goong Tseng, *Miami*  
Lyuba Varticovski, *Bethesda*  
Tandis Vazin, *Berkeley*  
Kent E Vrana, *Hershey*

Lyuba Varticovski, *Bethesda*  
Qi Wan, *Reno*  
Charles Wang, *Los Angeles*  
Guo-Shun Wang, *New Orleans*  
Zack Z Wang, *Scarborough*  
David Warburton, *Los Angeles*  
Li-Na Wei, *Jackson Hall*  
Andre Van Wijnen, *Worcester*  
Marc Adrian Williams, *Rochester*  
Joseph C Wu, *Stanford*  
Li-Zi Wu, *Gainesville*  
Sean M Wu, *Boston*  
Yan Xu, *Pittsburgh*  
Jun Yan, *Louisville*  
Jing Yang, *Orange*  
Li-Jun Yang, *Florida*  
Phillip Chung-Ming Yang, *Stanford*  
Pampee Paul Young, *Nashville*  
Hong Yu, *Miami*  
Seong-Woon Yu, *East Lansing*  
Xian-Min Zeng, *Novato*  
Bao-Hong Zhang, *Greenville*  
Ying Zhang, *Baltimore*  
Xue-Sheng Zheng, *Massachusetts*  
X Long Zheng, *Philadelphia*  
John F Zhong, *Los Angeles*



- ORIGINAL ARTICLE**      70      Characterization of mouse clonal mesenchymal stem cell lines established by subfractionation culturing method  
*Jeon MS, Yi TG, Lim HJ, Moon SH, Lee MH, Kang JS, Kim CS, Lee DH, Song SU*

**ACKNOWLEDGMENTS**     I     Acknowledgments to reviewers of *World Journal of Stem Cells*

**APPENDIX**     I     Meetings  
  
                          I-V     Instructions to authors

**ABOUT COVER**     Jeon MS, Yi TG, Lim HJ, Moon SH, Lee MH, Kang JS, Kim CS, Lee DH, Song SU. Characterization of mouse clonal mesenchymal stem cell lines established by subfractionation culturing method.  
*World J Stem Cells* 2011; 3(8): 70-82  
<http://www.wjgnet.com/1948-0210/full/v3/i8/70.htm>

**AIM AND SCOPE**     *World Journal of Stem Cells* (*World J Stem Cells, WJSC*, online ISSN 1948-0210, DOI: 10.4252), is a Monthly open-access peer-reviewed journal supported by an editorial board consisting of 284 experts in stem cell research from 28 countries.  
 The major task of *WJSC* is to rapidly report original articles and comprehensive reviews on basic laboratory investigations of stem cells and their application in clinical care and treatment of patients. *WJSC* is designed to cover all aspects of stem cells, including embryonic stem cells, neural stem cells, hematopoietic stem cells, mesenchymal stem cells, tissue-specific stem cells, cancer stem cells, the stem cell niche, stem cell genomics and proteomics, and translational and clinical research. In a word, papers published in *WJSC* will cover the biology, culture, and differentiation of stem cells from all stages of development from germ cell to embryo and adult.

**FLYLEAF**     I-III     Editorial Board

**EDITORS FOR THIS ISSUE**

**Responsible Assistant Editor:** *Le Zhang*  
**Responsible Electronic Editor:** *Jin-Lei Wang*  
**Proofing Editor-in-Chief:** *Lian-Sheng Ma*

**Responsible Science Editor:** *Jin-Lei Wang*  
**Proofing Editorial Office Director:** *Jin-Lei Wang*

**NAME OF JOURNAL**  
*World Journal of Stem Cells*

**LAUNCH DATE**  
 December 31, 2009

**SPONSOR**  
 Beijing Baishideng BioMed Scientific Co., Ltd., Room 903, Building D, Ocean International Center, No. 62 Dongsihuan Zhonglu, Chaoyang District, Beijing 100025, China  
 Telephone: +86-10-8538-1892  
 Fax: +86-10-8538-1893  
 E-mail: [baishideng@wjgnet.com](mailto:baishideng@wjgnet.com)  
<http://www.wjgnet.com>

**EDITING**  
 Editorial Board of *World Journal of Stem Cells*, Room 903, Building D, Ocean International Center, No. 62 Dongsihuan Zhonglu, Chaoyang District, Beijing 100025, China  
 Telephone: +86-10-8538-1891  
 Fax: +86-10-8538-1893  
 E-mail: [wjgc@wjgnet.com](mailto:wjgc@wjgnet.com)  
<http://www.wjgnet.com>

**PUBLISHING**  
 Baishideng Publishing Group Co., Limited, Room 1701, 17/F, Henan Bulding, No.90 Jaffe Road, Wanchai, Hong Kong, China

Fax: +852-3115-8812  
 Telephone: +852-5804-2046  
 E-mail: [baishideng@wjgnet.com](mailto:baishideng@wjgnet.com)  
<http://www.wjgnet.com>

**SUBSCRIPTION**  
 Beijing Baishideng BioMed Scientific Co., Ltd., Room 903, Building D, Ocean International Center, No. 62 Dongsihuan Zhonglu, Chaoyang District, Beijing 100025, China  
 Telephone: +86-10-8538-1892  
 Fax: +86-10-8538-1893  
 E-mail: [baishideng@wjgnet.com](mailto:baishideng@wjgnet.com)  
<http://www.wjgnet.com>

**PUBLICATION DATE**  
 August 26, 2011

**ISSN**  
 ISSN 1948-0210 (online)

**PRESIDENT AND EDITOR-IN-CHIEF**  
 Lian-Sheng Ma, *Beijing*

**STRATEGY ASSOCIATE EDITORS-IN-CHIEF**  
 Philippe Bourin, *Toulouse*  
 Andras Dinnyes, *Gadallo*  
 Umberto Galderisi, *Napoli*  
 Mikhail G Kolonin, *Houston*  
 Balazs Sarkadi, *Budapest*

**EDITORIAL OFFICE**  
 Jin-Lei Wang, Director  
*World Journal of Stem Cells*  
 Room 903, Building D, Ocean International Center, No. 62 Dongsihuan Zhonglu, Chaoyang District, Beijing 100025, China  
 Telephone: +86-10-8538-1891  
 Fax: +86-10-8538-1893  
 E-mail: [wjgc@wjgnet.com](mailto:wjgc@wjgnet.com)  
<http://www.wjgnet.com>

**COPYRIGHT**  
 © 2011 Baishideng. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

**SPECIAL STATEMENT**  
 All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

**INSTRUCTIONS TO AUTHORS**  
 Full instructions are available online at [http://www.wjgnet.com/1948-0210/g\\_info\\_20100313165700.htm](http://www.wjgnet.com/1948-0210/g_info_20100313165700.htm).

**ONLINE SUBMISSION**  
<http://www.wjgnet.com/1948-0210office>

## Characterization of mouse clonal mesenchymal stem cell lines established by subfractionation culturing method

Myung-Shin Jeon, Tac-Ghee Yi, Hyun-Ja Lim, Sun-Hwa Moon, Moon-Hee Lee, Joon-Soon Kang, Chul-Soo Kim, Dae-Hyun Lee, Sun U Song

Myung-Shin Jeon, Tac-Ghee Yi, Hyun-Ja Lim, Sun-Hwa Moon, Moon-Hee Lee, Joon-Soon Kang, Chul-Soo Kim, Dae-Hyun Lee, Sun U Song, Clinical Research Center, School of Medicine, Inha University, 7-206, 3-Ga, Shinheung-Dong, Chung-Gu, Incheon 400-711, South Korea

Author contributions: Jeon MS and Yi TG performed the majority of experiments; Lim HJ, Moon SH and Lee DH performed some experiments; Lee MH, Kang JS and Kim CS provided the materials and financial support for this work; Song SU designed the study and wrote the manuscript.

Supported by A Grant from the Korea Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (A092142), a research grant from HomeoTherapy Co. Ltd. (39856-01) and by the Brain Korea 21 Project in 2010

Correspondence to: Dr. Sun U Song, PhD, Professor, Clinical Research Center, College of Medicine, Inha University, 7-206, 3-Ga, Shinheung-Dong, Chung-Gu, Incheon 400-711, South Korea. [sunuksong@inha.ac.kr](mailto:sunuksong@inha.ac.kr)

Telephone: +82-32-8902460 Fax: +82-32-8902462

Received: August 10, 2010 Revised: January 10, 2011

Accepted: January 20, 2011

Published online: August 26, 2011

### Abstract

**AIM:** To characterize single-cell-derived mouse clonal mesenchymal stem cells (mcMSCs) established with bone marrow samples from three different mouse strains.

**METHODS:** We established mcMSC lines using subfractionation culturing method from bone marrow samples obtained from long bones. These lines were characterized by measuring cell growth, cell surface epitopes, differentiation potential, lineage-specific gene expression and T-cell suppression capability. Nonclonal MSCs isolated by the conventional gradient centrifugation method were used as controls.

**RESULTS:** All mcMSC lines showed typical nonclonal MSC-like spindle shape morphology. Lines differed in

optimal growth density requirement. Cell surface epitope profiles of these mcMSC lines were similar to those of nonclonal MSCs. However, some lines exhibited different expression levels in a few epitopes, such as CD44 and CD105. Differentiation assays showed that 90% of the mcMSC lines were capable of differentiating into adipogenic and/or chondrogenic lineages, but only 20% showed osteogenic lineage differentiation. T-cell suppression analysis showed that 75% of the lines exhibited T-cell suppression capability.

**CONCLUSION:** mcMSC lines have similar cell morphology and cell growth rate but exhibit variations in their cell surface epitopes, differentiation potential, lineage-specific gene expression and T-cell suppression capability.

© 2011 Baishideng. All rights reserved.

**Key words:** Clonal stem cells; Bone marrow stem cells; Multilineage differentiation; Clonal stromal cell isolation; T-cell suppression

**Peer reviewer:** Umberto Galderisi, PhD, Associate Professor, Department of Experimental Medicine, Second University of Naples, Via L. De Crecchio 7, 80138 Napoli, Italy

Jeon MS, Yi TG, Lim HJ, Moon SH, Lee MH, Kang JS, Kim CS, Lee DH, Song SU. Characterization of mouse clonal mesenchymal stem cell lines established by subfractionation culturing method. *World J Stem Cells* 2011; 3(8): 70-82 Available from: URL: <http://www.wjgnet.com/1948-0210/full/v3/i8/70.htm> DOI: <http://dx.doi.org/10.4252/wjsc.v3.i8.70>

### INTRODUCTION

Mesenchymal stem cells (MSCs) were first isolated from the bone marrow by Friedenstein *et al*<sup>[1]</sup> in the 1960s and they are now known to be present in a variety of tis-

sues, including adipose tissue, umbilical cord blood and muscle. MSCs can be readily obtained from humans and animals, isolated by means of their ability to adhere to plastic culture plates and can be expanded for many generations in culture.

The culture-expanded MSCs appear to have multi-lineage differentiation potential, including at least adipogenic, chondrogenic and osteogenic differentiation under appropriate induction conditions<sup>[2-4]</sup>. Recently, there have been reports regarding additional potential areas for lineage differentiation, such as neurogenic, cardiogenic, myogenic and hepatogenic differentiation<sup>[5-10]</sup>. Therefore, these cells are now also called multipotent stem/stromal cells since they are capable of differentiating into mesodermal, ectodermal and/or endodermal origin cells. In addition, more experimental data have become available about the immune modulation and hypoinmunogenic property of MSCs<sup>[11-16]</sup> and there has been a surge of interest in both the basic biology and the potential clinical applications of these cells.

The conventional isolation method of MSCs relies on the fractionation of mononuclear cells by gradient centrifugation and selection of fibroblast-like cells adhering to the culture plate surface by removing nonadherent floating cells. Experimental and clinical data over the last decade have indicated that cultured adherent MSCs are heterogeneous and exhibit variations in terms of their differentiation potentials and clinical outcomes<sup>[17,18]</sup>. In order to obtain more homogeneous MSC populations, fluorescence-activated cell sorting (FACS) isolation<sup>[19]</sup> and specific cell-surface antibody selection<sup>[20,21]</sup> have been applied, improving the purity of the final MSC population. However, although significant improvements have been made in purification techniques, these isolation methods have not yet been sufficient to isolate completely homogeneous populations of MSCs. The limiting dilution method has been the only option to generate single-cell-derived clonal MSC lines. Since a mononuclear cell fraction produced by gradient centrifugation or a culture-expanded population of MSCs was the usual source for the limiting dilution method, there is still a possibility of losing some “real” MSCs in the isolation of mononuclear cells and culture expansion of the cells.

Recently, we developed a new protocol, called the sub-fractionation culturing method (SCM), to generate single-cell-derived clonal MSC lines from whole bone marrow aspirate without any centrifugation step for mononuclear cells or enzyme treatment process. Using this method, we identified human bone marrow-derived, colony-forming fibroblastic cells as MSCs from relatively small amounts of bone marrow aspirates. This method allowed us to rapidly establish single-cell-derived human clonal MSC (hcMSC) lines from raw bone marrow aspirates and to establish a library of these hcMSC lines<sup>[22]</sup>. The rationale behind the SCM is that different types of mesenchymal stem or stromal cells can be isolated based on their cell densities and/or adherence to a plastic culture plate produced by a series of transfers of the culture supernatant

to subsequent dishes; thus, these low-density stem or stromal cells may have a higher proliferation and differentiation potential.

In the present work, we established single-cell-derived mouse clonal MSC (mcMSC) lines from mouse bone marrow samples from 3 different mouse strains and investigated their cell growth rate, cell surface epitopes, differentiation potentials, lineage-specific gene expression and T-cell suppression capability. The newly established mcMSC lines showed characteristics of progenitors and varied in terms of cell growth rate, cell surface epitopes, differentiation potential, lineage-specific gene expression and T-cell suppression ability, suggesting that variations of progenitor cells exist in mouse bone marrow. These kinds of highly homogeneous, single-cell-derived cMSCs will be very useful for both basic research and clinical applications of such cells.


## MATERIALS AND METHODS

### *Isolation and establishment of mcMSC lines*

Mouse bone marrow samples were harvested from tibiae and femurs of 5-wk-old BALB/c, C3H and C57/BL6 mice by flushing out the bone marrow cavity with 5-mL culture medium that comprised Dulbecco's modified Eagle's Medium (DMEM)-low glucose (GIBCO-BRL, Life Technologies, Gaithersburg, MD), 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. Then 15-mL of the complete growth medium was added to the mixture. This mixture was then incubated in a 100-mm culture dish. As shown in Figure 1, after incubation for 2 h at 37°C with 50 mL/L CO<sub>2</sub>, the supernatant only was transferred to a new, intermediate 100-mm dish. After the second 2-h incubation, the supernatant was transferred from the intermediate dish to a new dish (D1) and incubated for another 2 h. The supernatant was then transferred from D1 to a new dish (D2), incubated for 1 d, then transferred from D2 to a new dish (D3) and incubated for 1 d. This process was repeated 2 more times with 1- and 2-d incubation sequentially (for D4 and D5, respectively). After incubation for 7-14 d, the well-separated single-cell-derived colonies that appeared in the culture dishes were detached and isolated after a 2-3 min treatment with trypsin/ethylene diamine tetraacetic acid (EDTA) in cloning cylinders (GIBCO-BRL), transferred to a six-well plate, and then to larger culture flasks where they continued to expand. Once the cells reached approximately 80%-90% confluence, they were recovered with trypsin/EDTA and passaged at 50-100 cells/cm<sup>2</sup>. We obtained ten to twenty colonies on D1 to D3 dishes using bone marrow samples out of five mice and then were able to establish a total of seven, four and six mcMSC lines from each C3H, C57/BL6, Balb/c strain respectively. Out of these mcMSC lines, two lines from each strain were selected for this study.

### *Cell growth in vitro*

For analysis of proliferation ability, the established mc-



**Figure 1** Flow diagram of the “subfractionation culturing method” used to establish mouse clonal mesenchymal stem cell lines. Mouse bone marrow aspirate was mixed with Dulbecco’s modified Eagle’s Medium-low glucose and plated onto a 100-mm cell culture dish. After 2-h incubation, the supernatant only was transferred to a new dish. This procedure was repeated two more times, and then the supernatant was subsequently transferred to cell culture dishes with a 1- or 2-d interval as shown. Each dish was then incubated until single-cell-derived colonies appeared. When colonies of cells were large enough, they were transferred to a six-well plate or 100-mm cell culture dish and then expanded to larger flasks for freezing and further study. Unique mouse clonal mesenchymal stem cell (mcMSC) lines were saved in a mcMSC library.

MSC lines and nonclonal MSCs were seeded at a density of  $1 \times 10^3$ ,  $5 \times 10^3$ , or  $1 \times 10^4$  cells/60-mm dish and cultured in complete growth medium for 3, 7, 10 and 14 d. The culture medium was replaced every 3 d. The cell numbers were counted at each time point with a hemocytometer.

### Immunostaining and flow cytometry

For phenotyping of cell surface antigens, the established mcMSC lines at 5-7 passages were harvested from the 175-cm<sup>2</sup> flasks by treatment with trypsin/EDTA and washed twice with phosphate-buffered saline (PBS). The cells were incubated with fluorescein isothiocyanate (FITC)-conjugated antibodies for 30 min at 4°C. The cells were washed twice with PBS consisting of 0.1% bovine serum albumin (BSA). The following antibodies were used for flow cytometry: CD34 (Serotec, Oxford, UK), CD44 (Serotec), CD45 (BD Biosciences Pharmingen, San Diego, CA, USA), CD103 (BD Biosciences Pharmingen), CD105 (R&D Systems, Minneapolis, MN, USA), CD117 (BD Biosciences Pharmingen) and Sca-1 (BD Biosciences Pharmingen). The cells were washed twice with PBS consisting of 0.1% BSA and analyzed using flow cytometry with a 525-nm filter for green FITC fluorescence.

### In vitro differentiation

To compare the differentiation potential, the established mcMSC lines and nonclonal MSCs were induced to differentiate into adipogenic, osteogenic or chondrogenic lineage by using the following method.

For chondrogenic differentiation, a pellet culture system was used. Approximately  $2 \times 10^5$  mcMSCs or nonclonal MSCs were placed in a 15-mL polypropylene tube (Falcon, Bedford, MA, USA) and centrifuged to a pellet. The pellet was cultured at 37°C with 50 mL/L CO<sub>2</sub> in

500 µL chondrogenic differentiation medium composed of α-MEM supplemented with 10 ng/mL TGF-β1 (R&D Systems), 10 ng/mL TGF-β3 (R&D Systems), 50 µg/mL ascorbic acid (Sigma Chemical Co., St Louis, MO, USA),  $10^{-7}$  mol/L dexamethasone (Sigma Chemical Co.), 40 µg/mL proline (Sigma Chemical Co.) and 1% ITS<sup>+</sup> Premix (Becton Dickinson, Bedford, MA, USA; 6.25 µg/mL insulin, 6.25 µg/mL transferrin, 6.25 ng/mL selenious acid, 1.25 mg/mL BSA and 5.25 mg/mL linoleic acid). The chondrogenic differentiation medium was changed every 3 d for 3 wk. For microscopy, the pellets were embedded with an OCT compound (Sakura Finetek, Torrance, CA, USA), frozen sectioned into 8-µm sections and stained with toluidine blue or safranin O.

For investigating osteogenic and adipogenic differentiation, a monolayer culture system was used. For osteogenic differentiation, mcMSCs or nonclonal MSCs were plated at 50 cells/cm<sup>2</sup> in a 12-well plate and incubated until they reached confluence. The cultures were then incubated in osteogenic differentiation medium composed of α-MEM supplemented with 10% FBS, 50 µg/mL ascorbic acid (Sigma Chemical Co.),  $10^{-8}$  mol/L dexamethasone (Sigma Chemical Co.), 10 mmol/L β-glycerophosphate (Sigma Chemical Co.), and 1 mmol/L dibutyl-γ-cyclic AMP (db-cAMP). The db-cAMP was added only for the first 4 d. The medium was changed every 3 d for 3 wk. The cells were fixed with 10% formalin (Sigma Chemical Co.) for 10 min at room temperature and stained with 0.1% alizarin red S (Sigma Chemical Co.).

To evaluate adipogenic differentiation, mcMSCs or nonclonal MSCs were plated at 50 cells/cm<sup>2</sup> in a 12-well plate and incubated in α-MEM (20% FBS) until they reached confluence. The cultures were then incubated in adipogenic differentiation medium composed of DMEM-high glucose supplemented with 10% newborn calf serum,  $10^{-7}$  mol/L dexamethasone (Sigma Chemical Co.), 10 µg/mL insulin (Sigma Chemical Co.), 0.5 µmol/L 1-methyl-3-isobutylxanthine (IBMX; Sigma Chemical Co.) and 50 µg/mL indomethacin (Sigma Chemical Co.). The culture was incubated at 37°C with 50 mL/L CO<sub>2</sub> for 4 d. The cells were fixed with 10% formalin (Sigma Chemical Co.) for 10 min and stained with oil-red-O for 10 min at room temperature.

### RNA extraction and reverse transcriptase-polymerase chain reaction analysis

The total RNA was extracted from mcMSC lines grown either in complete growth medium or differentiation medium using easyBLUE® (Intron Biotechnology, Sungnam, Korea) reagent. The complementary DNA was synthesized using an AccuPower Reverse-Transcription kit (Bioneer, Daejeon, Korea) by following the manufacturer’s instructions. Polymerase chain reaction (PCR) was carried out using specific primers designed for each gene as follows: type I collagen α1 chain [ColA1, 587 base pair (bp)], forward primer 5'-ACGTCCTGGT-GAAGTTGGTC-3' and reverse primer 5'-AGCCAC-GATGACCCCTTTATG-3'; type II collagen α1 chain

(Col2A1, 418 bp), forward primer 5'-CTACTCAAGTCACTGAACAACCAGAT-3' and reverse primer 5'-CTGTTCTTACAGTGGTAGGTGATGTTCT-3'; type X collagen  $\alpha 1$  chain (Col10A1, 382 bp), forward primer 5'-GTCCAAGAGGTGAACCTGGA-3' and reverse primer 5'-GCACCTACTGCTGGGTAAGC-3'; aggrecan (Acan, 564 bp), forward primer 5'-GCGACATCTG-GAGTGAAGTGA-3' and reverse primer 5'-AGACA-CAGTGGGGAAACCTG-3'; lipoprotein lipase (LPL, 421 bp), forward primer 5'-GCGTAGCAGGAAGTC TGACC-3' and reverse primer 5'-CTACAACTCAG-GCAGAGCCC-3'; fatty acid-binding protein 4 (FABP4, 319 bp), forward primer 5'-AAAGAAGTGGGAGT-GGGCTT-3' and reverse primer 5'-CTCTTGTG-GAAGTCACGCCT-3'; peroxisome proliferator-activated receptor- $\gamma 2$  (PPAR- $\gamma 2$ , 377 bp), forward primer 5'-CT-TATTTATGATAGGTGTGATCTTAACTGC-3' and reverse primer 5'-GTGATATGTTTGAACCTTGATTT-TATCTTCT-3'; alkaline phosphatase (ALP, 555 bp), forward primer 5'-AACCAGACACAAGCATTCC-3' and reverse primer 5'-ACTGGGCCTGGTAGTTGTTG-3'; Distal-less homeobox 5 (Dlx5, 350 bp), forward primer 5'-CAGAAGAGTCCCAAGCATCC-3' and reverse primer 5'-CCACTTCTTCTCTGGCTGG-3'; Runx2 (469 bp), forward primer 5'-TGCGTATTCTGTAGATCCG-3' and reverse primer 5'-TAGTTCTCATCATTCCT GGC-3'; and glyceraldehyde phosphate dehydrogenase (GAPDH; 350 bp), forward primer 5'-AACTCCCTCA AGATTGTCAGCA-3' and reverse primer 5'-TCCAC-CACCCTGTTGCTTGTA-3'. PCR was performed for 30-40 cycles with each cycle involving denaturation at 94°C for 30 s, annealing at 58-60°C for 30 s and extension at 72°C for 1 min. The amplified PCR products were run on a 1% agarose gel.

### T-cell suppression analysis

Mouse splenocytes were cultured in RPMI supplemented with 10% FBS, 10 mmol/L HEPES, 2 mmol/L L-glutamine, 1 mmol/L sodium pyruvate, 50  $\mu$ mol/L  $\beta$ -mercaptoethanol, 100 g/mL penicillin and 100 g/mL streptomycin. Splenocytes were isolated from BALB/c spleen.  $2 \times 10^5$  cells were stimulated with 1  $\mu$ g/mL of anti-CD3 and anti-CD28 antibodies (BD Pharmingen, Franklin Lakes, NJ, USA) together with  $1 \times 10^4$  of indicated mcMSCs for 72 h. Proliferation of T cells was determined by incorporation of [ $^3$ H]-thymidine (1  $\mu$ Ci/well) for the last 12-16 h of culture. After 48-h stimulation, interferon- $\gamma$  (IFN- $\gamma$ ) was measured by ELISA according to the protocol of BD Pharmingen.

## RESULTS

### Establishment of mcMSC lines from mouse bone marrow aspirates

In order to establish mcMSC lines with mouse bone marrow samples from BALB/c, C3H and C57/BL6 strains, as described in the Materials and Methods, approximately 15-mL of each bone marrow mixture with

the complete culture medium mixture were plated in a 100-mm culture dish. Subsequently, the supernatant only was transferred to new culture dishes as described in Figure 1. Representative images of two single-cell-derived colonies from each strain and pictures of mcMSC lines and nonclonal MSCs are shown in Figure 2. The nonclonal MSCs isolated by the gradient centrifugation method (GCM) from the strains were used as control cells. These mcMSC lines established by the SCM are spindle-shaped fibroblast-like cells, which are similar to those of nonclonal MSCs.

### Cell proliferation of the established mcMSC lines

The cell growth rates of the established mcMSC lines and nonclonal MSCs were measured with 3 different starting cell densities,  $1 \times 10^3$ ,  $5 \times 10^3$ , and  $1 \times 10^4$  per 60-mm plate. As shown in Figure 3, all the lines except C57/BL6 D3-#1 showed exponential growth with starting populations of  $5 \times 10^3$  and  $1 \times 10^4$  cells. There was no significant difference between the GCM- or SCM-isolated cells in the proliferation rate for the 16 d of culture. No exponential growth was observed with the starting population of  $1 \times 10^3$  cells, suggesting that a certain initial number of cells are required for attaining proper growth phase of these cells.


### Cell surface epitopes of the established mcMSC lines

The cell surface epitopes of the mcMSC lines and nonclonal MSCs were compared by FACS analysis of a panel of eight cell surface proteins (Table 1). The results showed that all the mcMSC lines and nonclonal MSCs were strongly positive for Sca-1 and negative for CD34, HLA-DR, CD45, CD103 and CD117, as expected. One intriguing finding was that the mcMSC lines showed variations in their expressions of CD44 and CD105, as shown in Table 1. For example, BALB/c D1-#2, C3H D3-#2, C57/BL6 D3-#1 and C57/BL6 D3-#2 showed modest expression of CD44, whereas BALB/s GCM, C3H GCM and C3H D2-#1 were negative. In addition, BALB/c D2-#1 and C57/BL6 D3-#2 were strongly positive and BALB/c GCM, C3H D2-#1 and C3H D3-#2 were modestly positive for the expression of CD105, whereas C3H GCM, C57/BL6 GCM and C57/BL6 D3-#1 were negative. One observation we noticed was that one of the two mcMSC lines, C3H D3-#2, showed both CD44 and CD105 positive exhibited a high level of osteogenic differentiation potential. Other mcMSC lines and nonclonal MSCs showed either CD44 or CD105 positive.

These data demonstrate that the mcMSC lines established by the SCM exhibit variations in the expression of certain cell surface epitopes compared to those of nonclonal MSCs. The significance of these variations remains to be studied.

### Adipogenic differentiation potential of the established mcMSC lines

In order to examine the differentiation potential of the




**Figure 2** Pictures of the individual colonies and cell morphology of the established mouse clonal mesenchymal stem cell lines. A: Representative pictures of single colonies obtained from different strains; B: Pictures of mouse clonal mesenchymal stem cells (mcMSCs) established from single colonies at about 70%-80% confluence. Nonclonal MSCs isolated by the conventional method, labeled as the gradient centrifugation method, from the three strains are also shown. Every mcMSCs in the right panel have a fibroblast-like morphology. The cells were fixed with 4% paraformaldehyde for 10 min and stained with 0.1% crystal violet for 5 min. Magnification: 100 ×.

**Table 1** Cell surface epitopes of the established mouse clonal mesenchymal stem cell lines and nonclonal mesenchymal stem cells

	Sca-1	CD44	CD105	CD34	HLA-DR	CD45	CD103	CD117
BALB/c GCM	+++	-	+	-	-	-	-	-
BALB/c D1-#2	+++	+	-	-	-	-	-	-
BALB/c D2-#1	+++	-	++	-	-	-	-	-
C3H GCM	+++	-	-	-	-	-	-	-
C3H D2-#1	+++	-	+	-	-	-	-	-
C3H D3-#2	+++	+	+	-	-	-	-	-
C57BL/6 GCM	+++	+	-	-	-	-	-	-
C57BL/6 D3-#1	+++	++	-	-	-	-	-	-
C57BL/6 D3-#2	+++	+	++	-	-	-	-	-

-: Negative; +: 2%-20%; ++: 20%-70%; +++: 70%-100%.



**Figure 3** Cell growth of the established mouse clonal mesenchymal stem cell lines and nonclonal mesenchymal stem cells. Cells were plated at  $1 \times 10^3$ ,  $5 \times 10^3$ , or  $1 \times 10^4$  cells in a 60-mm dish and incubated in Dulbecco's modified Eagle's Medium-low glucose. Cells were trypsinized by incubation with trypsin/ethylene diamine tetraacetic acid and counted twice a week with a haemocytometer for 15 d. GCM: Gradient centrifugation method.

established mcMSC lines and nonclonal MSCs, *in vitro* adipogenic differentiation analysis was performed using

a monolayer culture system. Passage 6 mcMSCs from each of the cell lines were induced to differentiate into

adipocytes under the conditions described in Materials and Methods. As shown in Figure 4A, every mcMSC line showed a high level of adipogenic differentiation potential except C3H D3-#2. In contrast, the monolayer cells of both nonclonal and mcMSCs grown in the normal control medium showed no oil-red-O staining.

To further confirm the adipogenic differentiation potentials of the established mcMSC lines and nonclonal MSCs, reverse transcriptase-PCR (RT-PCR) assays using total mRNA from the cells were performed before and after induction of differentiation. The lineage-specific expression of adipogenic marker genes, *PPAR-γ2*, *FABP4*, *LPL* and *Col1A1* was measured at 0 and 4 d after induction of differentiation. As shown in Figure 4B, the expression of *PPAR-γ2*, *FABP4* and *LPL* was upregulated in most of the cells, whereas the expression of *Col1A1* was downregulated as expected. These results suggest that both mcMSCs and nonclonal MSCs have a high potential for adipogenic differentiation.

#### **Osteogenic differentiation potential of the established mcMSC lines**

To examine the osteogenic differentiation potential of the established mcMSC lines and nonclonal MSCs, *in vitro* differentiation analyses were performed using a monolayer culture system for osteogenic differentiation. Passage 6 mcMSCs from each cell line were induced to differentiate into osteoblasts under the conditions described in Materials and Methods. As shown in Figure 5A, among the twelve tested lines, only one nonclonal MSC line, C57/BL6 GCM, and one mcMSC line, C3H D3-#2, exhibited a high level of osteogenic differentiation potential, whereas other nonclonal and mcMSCs showed no differentiation potential. The monolayer cells of both nonclonal and mcMSCs grown in the normal control medium were negative for Alizarin Red S.

To further confirm the osteogenic differentiation capabilities of the mcMSC lines and nonclonal MSCs, RT-PCR assays were performed using total mRNA from cells before and after induction of differentiation. The lineage-specific expression of osteogenic marker genes, *ALP*, *Runx2*, *Colα1* and *Dlx5* were measured at 0 and 7 d after differentiation induction. As seen in Figure 5B, the expression of *ALP*, *Runx2*, *Colα1* and *Dlx5* was upregulated in C3H D3-#2 and C57/BL6 GCM cells.

#### **Chondrogenic differentiation potential of the established mcMSC lines**

To examine the chondrogenic differentiation potential of the established mcMSC lines and nonclonal MSCs, *in vitro* chondrogenic differentiation analysis was performed using a pellet culture system. Passage 6 mcMSCs from each cell line were induced to differentiate into chondrocytes under the conditions described in Materials and Methods. As shown in Figure 6A, every mcMSC line showed a high level of chondrogenic differentiation potential except BALB/c GCM and D2-#1. In contrast, the control mon-

olayer cells grown in the normal medium exhibited only slight safranin O staining.

To further confirm the chondrogenic differentiation capabilities of the mcMSC lines and nonclonal MSCs, RT-PCR assays were performed using total mRNA from cells before and after induction of differentiation. The lineage-specific expression of chondrogenic marker genes, *Col1A1*, *Acan* and *Col10A1* were measured at 0 and 21 d after differentiation induction. As seen in Figure 6B, the expressions of *Col1A1*, *Acan* and *Col10A1* were observed to be upregulated.


#### **T-cell suppression potential of the established mcMSC lines**

To test the immunosuppressive potential of mcMSC lines and nonclonal MSCs, mixed lymphocyte reaction analysis was performed with the cells. The formation of T-cell receptor (TCR)-activated T-cell clusters, IFN-γ production suppression and T-cell proliferation inhibition were measured with antibody-activated splenocytes in the presence of each mcMSC line or nonclonal MSCs. As shown in Figure 7A, the number of TCR activated T-cell clusters were reduced in BALB/c D2-#1, C57/BL6 GCM, D3-#1, D3-#2 and C3H D3-#2 cells, whereas other MSCs showed less or no reduction. The results of the IFN-γ production suppression and T-cell proliferation inhibition experiments were highly comparable to the T-cell cluster results except for C57/BL6 GCM cells. These data suggest that the T-cell suppression potential may vary from mcMSC line to mcMSC line.


## **DISCUSSION**

In this paper, single-cell-derived mcMSC lines were established using the SCM and characterized for their proliferation, cell surface epitopes, differentiation potential, lineage-specific gene expression and T-cell suppression capability. The results suggest that mcMSC lines are readily established using the SCM protocol and that some of the newly established mcMSCs have stem/progenitor cell characteristics with variations in their cell surface epitopes, differentiation potential, lineage-specific gene expression and T-cell suppression capability.


In spite of recent high levels of experimental and clinical interest, a standard protocol for producing homogeneous populations of MSCs has not yet been available. The homogeneity of MSCs has become an important issue in terms of understanding the molecular characterization of MSCs and also for applying them in clinical settings. For example, several studies have investigated the gene expression profiles of MSCs to understand the molecular properties of MSCs such as stemness, self-renewal and differentiation potential. Although very informative, most of these studies have limitations due to the heterogeneity of MSCs used in the experiments. In addition, heterogeneous populations of MSCs might possibly generate various efficacies in the treatment of disease. A mixed population of mononuclear cells has been




**Figure 4** Adipogenic differentiation potential of the established mouse clonal mesenchymal stem cell lines and nonclonal mesenchymal stem cells. **A:** Oil-red-O staining showed that adipogenically differentiated mouse clonal mesenchymal stem cell lines were positive, tested 4 d after adipogenic induction: a and b: BALB/c gradient centrifugation method (GCM); c and d: BALB/c D1-#2; e and f: BALB/c D2-#1; g and h: C3H GCM; i and j: C3H D2-#1; k and l: C3H D3-#2; m and n: C57BL/6 GCM; o and p: C57BL/6 D3-#1; q and r: C57BL/6 D3-#2; **B:** Reverse transcriptase-polymerase chain reaction analysis of the adipogenic markers peroxisome proliferator-activated receptor  $\gamma$ 2 (PPAR $\gamma$ 2), fatty acid-binding protein 4, lipoprotein lipase (LPL), and Col1A1 at days 0 and 4 after adipogenic induction. glyceraldehyde phosphate dehydrogenase was used as an internal control.



**Figure 5** Osteogenic differentiation potentials of the established mouse clonal mesenchymal stem cell lines and nonclonal mesenchymal stem cells. **A:** Alizarin Red S staining showed matrix mineralization in the osteogenically differentiated mouse clonal mesenchymal stem cell lines 21 d after osteogenic induction: a and b: BALB/c gradient centrifugation method (GCM); c and d: BALB/c D1-#2; e and f: BALB/c D2-#1; g and h: C3H GCM; i and j: C3H D2-#1; k and l: C3H D3-#2; m and n: C57BL/6 GCM; o and p: C57BL/6 D3-#1; q and r: C57BL/6 D3-#2; **B:** Reverse transcriptase-polymerase chain reaction analysis of osteogenic markers, alkaline phosphatase (ALP), Runx-2, Col1A1, and Distal-less homeobox 5 at days 0 and 7 after osteogenic induction. Glyceraldehyde phosphate dehydrogenase was used as an internal control.



**Figure 6** Chondrogenic differentiation potential of the established mouse clonal mesenchymal stem cell lines and nonclonal mesenchymal stem cells. **A:** Histochemical staining with Safranin-O showed chondrogenically differentiated mouse clonal mesenchymal stem cell lines, tested 21 d after chondrogenic induction: a and b: BALB/c gradient centrifugation method (GCM); c and d: BALB/c D1-#2; e and f: BALB/c D2-#1; g and h: C3H GCM; i and j: C3H D2-#1; k and l: C3H D3-#2; m and n: C57BL/6 GCM; o and p: C57BL/6 D3-#1; q and r: C57BL/6 D3-#2; **B:** Reverse transcriptase-polymerase chain reaction analysis of chondrogenic markers, type II collagen, aggrecan, and type X collagen at days 0 and 21 after chondrogenic induction. Glyceraldehyde phosphate dehydrogenase was used as an internal control.



**Figure 7** Immunosuppressive effect of mouse clonal mesenchymal stem cell lines or nonclonal mesenchymal stem cells on T cells. Splenocytes ( $2 \times 10^5$ ) from BALB/c were stimulated with soluble anti-CD3 ( $1 \mu\text{g/mL}$ ) and anti-CD28 ( $1 \mu\text{g/mL}$ ) in the presence of  $1 \times 10^4$  different mesenchymal stem cells. A: After 48 h, T-cell receptor-activated T-cell clusters were observed by microscopy; B: Interferon (IFN)- $\gamma$  production was determined by ELISA; C: T-cell proliferation was determined by [ $^3\text{H}$ ]-thymidine incorporation after 3 d culture. GCM: Gradient centrifugation method.

used in most preclinical and clinical studies so far<sup>[18]</sup>. The benefit of using a mixed population of MSCs *vs* clonally expanded MSCs from bone marrow for a clinical trial has yet to be adequately investigated. In order to obtain more homogeneous populations of MSCs, antibody selection of specific surface antigen- expressing MSCs<sup>[20,21]</sup>, FACS sorting of specific sizes of MSCs<sup>[19]</sup> and clonal selection by limiting dilution have been utilized. Recently, we developed the SCM and reported how to establish human bone marrow-derived cMSC lines. This method allows a rapid establishment of single-cell-derived clonal MSC lines with a small amount of bone marrow aspirate and could be a very useful protocol with which to obtain highly homogeneous population of MSCs<sup>[22]</sup>. The establishment of mcMSC lines from three different mouse strains, as shown in the present study, and our previous success with human bone marrow strongly suggests that the SCM is universally applicable in establishing clonal stem cell lines from relatively small amounts of bone marrow samples regardless of species. We have also succeeded in establishing cMSC lines with rat and rabbit bone marrow aspirates (unpublished data). Therefore, the advantages of the SCM are as follows: Firstly, this

method does not require any centrifugation step in the whole procedure. Secondly, it does not require any enzymatic process or filtering procedure. Thirdly, it can generate single-cell-derived homogeneous clonal MSC lines. Fourthly, the protocol works well for bone marrow samples from different species, including human, mouse, rat and rabbit. These advantages suggest that the SCM can generate a homogeneous population of MSCs in a simple, effective and economic way and may allow safer applications in therapeutic settings.

One difference we have observed while establishing and characterizing mouse and human cMSC lines was the number of lines with osteogenic differentiation potential. The frequency of obtaining cMSC lines with osteogenic differentiation potential was approximately five times lower with mouse bone marrow samples than that with human bone marrow. This difference may be just a simple species difference or might be caused by the source of mouse and human bone marrow; the mouse bone marrow was from long bones whereas the human bone marrow was from the iliac crest. Enzymatic treatment of bone marrow, such as with collagenase, might improve the number of mouse lines with osteogenic differentia-

tion potential. Although there was no correlation between the cell surface marker expression and differentiation potential, one observation we noticed was that one of the two mcMSC lines, C3H D3-#2, showed both CD44 and CD105 positive exhibited a high level of osteogenic differentiation potential. Other mcMSC lines and nonclonal MSCs showed either CD44 or CD105 positive.

The rapid establishment of mcMSC lines and variations of the lines in phenotype, differentiation potential, gene expression and T-cell suppression capacity encouraged us to establish a mcMSC library of a variety of different mcMSC lines. This kind of library will be very useful for both the basic study of bone-marrow-derived stem cells and for clinical study of specific target disease treatment. For example, a cMSC line exhibiting great capability for inhibition of T-cell proliferation would be an excellent candidate stem cell for the development of a stem cell product to treat graft-versus-host disease. One potential concern of using clonal MSC lines is their tumorigenicity potential. Thus, we have tested the transformation potential of seven hcMSC lines by *in vitro*-transformation assay with human HeLa tumor cell line as a positive control and mouse NIH3T3 cell line as a negative control. The results showed that our hcMSC lines produces a smaller number of colonies than do NIH3T3 cells (data not shown), suggesting that the hcMSC lines are probably not tumorigenic.

In conclusion, this study reports a protocol that allows the rapid establishment of mcMSC lines with a small amount of mouse bone marrow. Some of the newly established mcMSC lines exhibit stem/progenitor cell characteristics with some variations in their cell surface epitopes, differentiation potential, lineage-specific gene expression and T cell suppression capability, indicating the presence of different types of stem/progenitor cells in the bone marrow. This protocol will allow easy construction of a mcMSC library containing a variety of different types of bone marrow mcMSC lines. These types of different homogeneous populations of cMSC lines will likely have useful applications in both basic research and clinical applications.

## COMMENTS

### Background

The conventional isolation method of mesenchymal stem cells (MSCs) relies on the fractionation of mononuclear cells by gradient centrifugation and selection of fibroblast-like cells adhering to the culture plate surface by removing nonadherent floating cells. Experimental and clinical data over the last decade have indicated that cultured adherent MSCs are heterogeneous and exhibit variations in terms of their differentiation potentials and clinical outcomes. In order to obtain more homogeneous MSC populations, fluorescence-activated cell sorting (FACS) isolation and specific cell-surface antibody selection have been applied, improving the purity of the final MSC population. However, although significant improvements have been made in purification techniques, these isolation methods have not yet been sufficient to isolate completely homogeneous populations of MSCs.

### Research frontiers

In order to obtain more homogeneous MSC populations, FACS isolation and specific cell-surface antibody selection have been applied, improving the purity of the final MSC population. However, although significant improvements have

been made in purification techniques, these isolation methods have not yet been sufficient to isolate completely homogeneous populations of MSCs.

### Innovations and breakthroughs

The advantages of the subfractionation culturing method (SCM) are as follows: Firstly, this method does not require any centrifugation step in the whole procedure. Secondly, it does not require any enzymatic process or filtering procedure. Thirdly, it can generate single-cell-derived homogeneous clonal MSC lines. Fourthly, the protocol works well for bone marrow samples from different species, including human, mouse, rat and rabbit. These advantages suggest that the SCM can generate a homogeneous population of MSCs in a simple, effective and economic way and may allow safer applications in therapeutic settings.

### Applications

The results in this study suggest that SCM allows the rapid establishment of mouse clonal MSC (mcMSC) lines with a small amount of mouse bone marrow. This protocol will allow easy construction of a mcMSC library containing a variety of different types of bone marrow mcMSC lines. These types of different homogeneous populations of cMSC lines will likely have useful applications in both basic research and clinical applications.

### Terminology

MSC: These stem cells were first isolated from the bone marrow in the 1960s and they are now known to be present in a variety of tissues, including adipose tissue, umbilical cord blood and muscle. They can be differentiated into adipocytes, chondrocytes, osteoblasts, neurons, cardiocytes and hepatocytes. SCM: A newly developed method to isolate clonal MSCs which are derived from a single stem cell so that these cells can be highly homogeneous.

### Peer review

The authors described a simplified protocol to obtain clonal mouse MSCs. The paper is of interest since a lot of data have been collected on the set up of a proper method to isolate MSCs. The paper is well written and the study well conducted.

## REFERENCES

- 1 **Friedenstein AJ**, Petrakova KV, Kurolesova AI, Frolova GP. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. *Transplantation* 1968; **6**: 230-247
- 2 **Pittenger MF**, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. *Science* 1999; **284**: 143-147
- 3 **Phinney DG**, Kopen G, Isaacson RL, Prockop DJ. Plastic adherent stromal cells from the bone marrow of commonly used strains of inbred mice: variations in yield, growth, and differentiation. *J Cell Biochem* 1999; **72**: 570-585
- 4 **Schwarz EJ**, Alexander GM, Prockop DJ, Azizi SA. Multipotential marrow stromal cells transduced to produce L-DOPA: engraftment in a rat model of Parkinson disease. *Hum Gene Ther* 1999; **10**: 2539-2549
- 5 **Woodbury D**, Schwarz EJ, Prockop DJ, Black IB. Adult rat and human bone marrow stromal cells differentiate into neurons. *J Neurosci Res* 2000; **61**: 364-370
- 6 **Wakitani S**, Saito T, Caplan AL. Myogenic cells derived from rat bone marrow mesenchymal stem cells exposed to 5-azacytidine. *Muscle Nerve* 1995; **18**: 1417-1426
- 7 **Prockop DJ**, Azizi SA, Colter D, Digirolamo C, Kopen G, Phinney DG. Potential use of stem cells from bone marrow to repair the extracellular matrix and the central nervous system. *Biochem Soc Trans* 2000; **28**: 341-345
- 8 **Toma C**, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. *Circulation* 2002; **105**: 93-98
- 9 **Liechty KW**, MacKenzie TC, Shaaban AF, Radu A, Moseley AM, Deans R, Marshak DR, Flake AW. Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. *Nat Med* 2000; **6**: 1282-1286

- 10 **Petersen BE**, Bowen WC, Patrene KD, Mars WM, Sullivan AK, Murase N, Boggs SS, Greenberger JS, Goff JP. Bone marrow as a potential source of hepatic oval cells. *Science* 1999; **284**: 1168-1170
- 11 **Di Nicola M**, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, Gianni AM. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. *Blood* 2002; **99**: 3838-3843
- 12 **Le Blanc K**, Tammik C, Rosendahl K, Zetterberg E, Ringdén O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. *Exp Hematol* 2003; **31**: 890-896
- 13 **Götherström C**, Ringdén O, Westgren M, Tammik C, Le Blanc K. Immunomodulatory effects of human foetal liver-derived mesenchymal stem cells. *Bone Marrow Transplant* 2003; **32**: 265-272
- 14 **Le Blanc K**, Rasmusson I, Götherström C, Seidel C, Sundberg B, Sundin M, Rosendahl K, Tammik C, Ringdén O. Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. *Scand J Immunol* 2004; **60**: 307-315
- 15 **Aggarwal S**, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. *Blood* 2005; **105**: 1815-1822
- 16 **Krampera M**, Pasini A, Pizzolo G, Cosmi L, Romagnani S, Annunziato F. Regenerative and immunomodulatory potential of mesenchymal stem cells. *Curr Opin Pharmacol* 2006; **6**: 435-441
- 17 **Uccelli A**, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. *Nat Rev Immunol* 2008; **8**: 726-736
- 18 **Rosenzweig A**. Cardiac cell therapy--mixed results from mixed cells. *N Engl J Med* 2006; **355**: 1274-1277
- 19 **Zohar R**, Sodek J, McCulloch CA. Characterization of stromal progenitor cells enriched by flow cytometry. *Blood* 1997; **90**: 3471-3481
- 20 **Joyner CJ**, Bennett A, Triffitt JT. Identification and enrichment of human osteoprogenitor cells by using differentiation stage-specific monoclonal antibodies. *Bone* 1997; **21**: 1-6
- 21 **Waller EK**, Olweus J, Lund-Johansen F, Huang S, Nguyen M, Guo GR, Terstappen L. The "common stem cell" hypothesis reevaluated: human fetal bone marrow contains separate populations of hematopoietic and stromal progenitors. *Blood* 1995; **85**: 2422-2435
- 22 **Song SU**, Kim CS, Yoon SP, Kim SK, Lee MH, Kang JS, Choi GS, Moon SH, Choi MS, Cho YK, Son BK. Variations of clonal marrow stem cell lines established from human bone marrow in surface epitopes, differentiation potential, gene expression, and cytokine secretion. *Stem Cells Dev* 2008; **17**: 451-461

S- Editor Wang JL L- Editor Roemmele A E- Editor Zheng XM

## Acknowledgments to reviewers of *World Journal of Stem Cells*

Many reviewers have contributed their expertise and time to the peer review, a critical process to ensure the quality of *World Journal of Stem Cells*. The editors and authors of the articles submitted to the journal are grateful to the following reviewers for evaluating the articles (including those published in this issue and those rejected for this issue) during the last editing time period.

**Yusuke Furukawa, MD, PhD**, Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University School of Medicine, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan

**Zhong-Chao Han, MD, PhD, Professor**, Institute of Hematology, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China

**Xiao-Yan Jiang, MD, PhD, Associate Professor**, Medical Genetics, University of British Columbia, Senior Scientist, Terry Fox Laboratory, BC Cancer Agency Research Centre, 675 West 10th Avenue, Vancouver, BC V5Z 1L3, Canada

**Hiroyuki Miyoshi, PhD**, Subteam for Manipulation of Cell Fate, BioResourceCenter, RIKEN, 3-1-1 Koyadai, Tsukuba, Ibaraki 305-0074, Japan

**Heli Teija Kristiina Skottman, PhD**, Academy of Finland Research fellow, Regea Institute for Regenerative medicine, University of Tampere, Finland, Biokatu 12, 33520 Tampere, Finland

**Soren Paludan Sheikh, MD, PhD, Professor**, Department

of Biochemistry, Pharmacology and Genetics, Odense University Hospital, University of Southern Denmark, Sdr. Boulevard 29, DK 5000, Denmark

**Ludwig Aigner, PhD, Professor**, Institute of Molecular Regenerative Medicine, Paracelsus Medical University, Strubergasse 21, A-5020 Salzburg, Austria

**Borhane Annabi, PhD, Professor**, Department of Chemistry, Biomed Research Centre, Université du Québec à Montréal Montreal, Quebec, H2X 2J6, Canada

**Denis Corbeil, PhD**, Tissue Engineering Laboratories, Biotec, Medical Faculty, Technical University of Dresden, Tatzberg 47-49, 01307, Dresden, Germany

**Mieke Geens, PhD**, EMGE, UZ Brussel, Laarbeeklaan 101, 1090 Jette, Brussels, Belgium

**Alice Pébay, PhD**, Centre for Neuroscience & Department of Pharmacology, University of Melbourne, Parkville VIC 3010, Australia

**John F Zhong, PhD, Assistant Professor**, School of Medicine, University of Southern California, 2025 Zonal Ave, RMR 210, Los Angeles, CA 90033, United States

**Hong Yu, PhD**, Miami VA Health Care System, 1201 NW 16th St, Research 151, Miami, FL 33125, United States

**Andre Van Wijnen, PhD**, Department of Cell Biology, Rm S3-322, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, United States

## Events Calendar 2011

March 26, 2011

Stem Cell Agency Governance  
 Subcommittee Meeting, Crowne  
 Plaza SFO, 1177 Airport Blvd,  
 Burlingame, CA,  
 United States

January 29-February 2, 2011  
 LabAutomation2011,  
 Palm Springs, CA, United States

February 4, 2011  
 7th annual Swiss Stem Cell Network  
 meeting, Swiss Federal Institute  
 of Technology in Lausanne,  
 Switzerland

March 1, 2011  
 The 6th Annual Stem Cell Summit,

11 Fulton Street, New York City, NY,  
 United States

March 22, 2011  
 StemCONN 2011, Farmington, CT,  
 United States

March 27-31, 2011  
 SBS 17th Annual Conference and  
 Exhibition, Orlando, FL, United States

April 6-8, 2011  
 EMBO Conference-Advances in  
 Stem Cell Research: Development,  
 Regeneration and Disease,  
 Institut Pasteur, Paris,  
 France

April 7-10, 2011  
 2011 CSHL Meeting on Stem Cell  
 Engineering & Cell Therapy, Cold

Spring Harbor Laboratory, Cold  
 Spring Harbor, NY, United States

April 25-26, 2011  
 International Conference on Stem  
 Cell Research, Hotel Equatorial  
 Penang, Malaysia

April 27, 2011  
 6th Annual Wisconsin Stem Cell  
 Symposium, BioPharmaceutical  
 Technology Center, Madison, WI,  
 United States

May 9-11, 2011  
 The World Stem Cells and  
 Regenerative Medicine Congress  
 2011, Victoria Park Plaza, London,  
 United Kingdom

May 23-24, 2011

The 4th Annual Israeli Stem Cell  
 Meeting, Beit Sourasky,  
 Chaim Sheba Medical Center,  
 Israel

May 26-27, 2011  
 7th annual Stem Cell Research &  
 Therapeutics Conference, Boston,  
 MA, United States

September 20-24, 2011  
 2011 CSHL Meeting on Stem  
 Cell Biology, Cold Spring  
 Harbor Laboratory, Cold Spring  
 Harbor, NY, United States

October 2011  
 3rd Annual World Stem Cells &  
 Regenerative Medicine  
 Congress Asia 2011, Seoul,  
 South Korea

**GENERAL INFORMATION**

*World Journal of Stem Cells* (*World J Stem Cells*, *WJSC*, online ISSN 1948-0210, DOI: 10.4252), is a monthly, open-access (OA), peer-reviewed journal supported by an editorial board of 284 experts in stem cell from 28 countries.

The biggest advantage of the OA model is that it provides free, full-text articles in PDF and other formats for experts and the public without registration, which eliminates the obstacle that traditional journals possess and usually delays the speed of the propagation and communication of scientific research results. The open access model has been proven to be a true approach that may achieve the ultimate goal of the journals, i.e. the maximization of the value to the readers, authors and society.

**Maximization of personal benefits**

The role of academic journals is to exhibit the scientific levels of a country, a university, a center, a department, and even a scientist, and build an important bridge for communication between scientists and the public. As we all know, the significance of the publication of scientific articles lies not only in disseminating and communicating innovative scientific achievements and academic views, as well as promoting the application of scientific achievements, but also in formally recognizing the "priority" and "copyright" of innovative achievements published, as well as evaluating research performance and academic levels. So, to realize these desired attributes of *WJSC* and create a well-recognized journal, the following four types of personal benefits should be maximized. The maximization of personal benefits refers to the pursuit of the maximum personal benefits in a well-considered optimal manner without violation of the laws, ethical rules and the benefits of others. (1) Maximization of the benefits of editorial board members: The primary task of editorial board members is to give a peer review of an unpublished scientific article *via* online office system to evaluate its innovativeness, scientific and practical values and determine whether it should be published or not. During peer review, editorial board members can also obtain cutting-edge information in that field at first hand. As leaders in their field, they have priority to be invited to write articles and publish commentary articles. We will put peer reviewers' names and affiliations along with the article they reviewed in the journal to acknowledge their contribution; (2) Maximization of the benefits of authors: Since *WJSC* is an open-access journal, readers around the world can immediately download and read, free of charge, high-quality, peer-reviewed articles from *WJSC* official website, thereby realizing the goals and significance of the communication between authors and peers as well as public reading; (3) Maximization of the benefits of readers: Readers can read or use, free of charge, high-quality peer-reviewed articles without any limits, and cite the arguments, viewpoints, concepts, theories, methods, results, conclusion or facts and data of pertinent literature so as to validate the innovativeness, scientific and practical values of their own research achievements, thus ensuring that their articles have novel arguments or viewpoints, solid evidence and correct conclusion; and (4) Maximization of the benefits of employees: It is an iron law that a first-class journal is unable to exist without first-class editors, and only first-class editors can create a first-class academic journal. We insist on strengthening our team cultivation and construction so that every employee, in an open, fair and transparent environment, could contribute their wisdom to edit and publish high-quality ar-

ticles, thereby realizing the maximization of the personal benefits of editorial board members, authors and readers, and yielding the greatest social and economic benefits.

**Aims and scope**

The major task of *WJSC* is to report rapidly original articles and comprehensive reviews on basic laboratory investigations of stem cells and their application in clinical care and treatment of patients. *WJSC* is designed to cover all aspects of stem cells, including: Embryonic, neural, hematopoietic, mesenchymal, tissue-specific, and cancer stem cells; the stem cell niche; stem cell genomics and proteomics; and stem cell techniques and their application in clinical trials. Papers published in *WJSC* will cover the biology, culture, differentiation and application of stem cells from all stages of their development, from germ cell to embryo and adult.

**Columns**

The columns in the issues of *WJSC* will include: (1) Editorial: To introduce and comment on major advances and developments in the field; (2) Frontier: To review representative achievements, comment on the state of current research, and propose directions for future research; (3) Topic Highlight: This column consists of three formats, including (A) 10 invited review articles on a hot topic, (B) a commentary on common issues of this hot topic, and (C) a commentary on the 10 individual articles; (4) Observation: To update the development of old and new questions, highlight unsolved problems, and provide strategies on how to solve the questions; (5) Guidelines for Basic Research: To provide guidelines for basic research; (6) Guidelines for Clinical Practice: To provide guidelines for clinical diagnosis and treatment; (7) Review: To review systemically progress and unresolved problems in the field, comment on the state of current research, and make suggestions for future work; (8) Original Articles: To report innovative and original findings in stem cells; (9) Brief Articles: To briefly report the novel and innovative findings in stem cells; (10) Case Report: To report a rare or typical case; (11) Letters to the Editor: To discuss and make reply to the contributions published in *WJSC*, or to introduce and comment on a controversial issue of general interest; (12) Book Reviews: To introduce and comment on quality monographs of stem cells; and (13) Guidelines: To introduce consensus and guidelines reached by international and national academic authorities worldwide on the research in stem cells.

**Name of journal**

*World Journal of Stem Cells*

**ISSN**

ISSN 1948-0210 (online)

**Indexed and Abstracted in**

PubMed Central, PubMed, Digital Object Identifier, and Directory of Open Access Journals.

**Published by**

Baishideng Publishing Group Co., Limited

**SPECIAL STATEMENT**

All articles published in this journal represent the viewpoints of the

## Instructions to authors

authors except where indicated otherwise.

### **Biostatistical editing**

Statistical review is performed after peer review. We invite an expert in Biomedical Statistics from to evaluate the statistical method used in the paper, including *t*-test (group or paired comparisons), chi-squared test, Ridit, probit, logit, regression (linear, curvilinear, or stepwise), correlation, analysis of variance, analysis of covariance, *etc.* The reviewing points include: (1) Statistical methods should be described when they are used to verify the results; (2) Whether the statistical techniques are suitable or correct; (3) Only homogeneous data can be averaged. Standard deviations are preferred to standard errors. Give the number of observations and subjects (*n*). Losses in observations, such as drop-outs from the study should be reported; (4) Values such as ED50, LD50, IC50 should have their 95% confidence limits calculated and compared by weighted probit analysis (Bliss and Finney); and (5) The word 'significantly' should be replaced by its synonyms (if it indicates extent) or the *P* value (if it indicates statistical significance).

### **Conflict-of-interest statement**

In the interests of transparency and to help reviewers assess any potential bias, *WJSC* requires authors of all papers to declare any competing commercial, personal, political, intellectual, or religious interests in relation to the submitted work. Referees are also asked to indicate any potential conflict they might have reviewing a particular paper. Before submitting, authors are suggested to read "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest" from International Committee of Medical Journal Editors (ICMJE), which is available at: [http://www.icmje.org/ethical\\_4conflicts.html](http://www.icmje.org/ethical_4conflicts.html).

Sample wording: [Name of individual] has received fees for serving as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. [Name of individual] is an employee of [name of organization]. [Name of individual] owns stocks and shares in [name of organization]. [Name of individual] owns patent [patent identification and brief description].

### **Statement of informed consent**

Manuscripts should contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee or it should be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. Authors should also draw attention to the Code of Ethics of the World Medical Association (Declaration of Helsinki, 1964, as revised in 2004).

### **Statement of human and animal rights**

When reporting the results from experiments, authors should follow the highest standards and the trial should conform to Good Clinical Practice (for example, US Food and Drug Administration Good Clinical Practice in FDA-Regulated Clinical Trials; UK Medicines Research Council Guidelines for Good Clinical Practice in Clinical Trials) and/or the World Medical Association Declaration of Helsinki. Generally, we suggest authors follow the lead investigator's national standard. If doubt exists whether the research was conducted in accordance with the above standards, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

Before submitting, authors should make their study approved by the relevant research ethics committee or institutional review board. If human participants were involved, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and appropriate informed consent of each. Any personal item or information will not be published without explicit consents from the involved patients. If experimental animals were used, the materials and methods (experimental procedures) section must clearly indicate that appropriate measures were taken

to minimize pain or discomfort, and details of animal care should be provided.

## SUBMISSION OF MANUSCRIPTS

Manuscripts should be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Number all pages consecutively, and start each of the following sections on a new page: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Figures, and Figure Legends. Neither the editors nor the publisher are responsible for the opinions expressed by contributors. Manuscripts formally accepted for publication become the permanent property of Baishideng Publishing Group Co., Limited, and may not be reproduced by any means, in whole or in part, without the written permission of both the authors and the publisher. We reserve the right to copy-edit and put onto our website accepted manuscripts. Authors should follow the relevant guidelines for the care and use of laboratory animals of their institution or national animal welfare committee. For the sake of transparency in regard to the performance and reporting of clinical trials, we endorse the policy of the ICMJE to refuse to publish papers on clinical trial results if the trial was not recorded in a publicly-accessible registry at its outset. The only register now available, to our knowledge, is <http://www.clinicaltrials.gov> sponsored by the United States National Library of Medicine and we encourage all potential contributors to register with it. However, in the case that other registers become available you will be duly notified. A letter of recommendation from each author's organization should be provided with the contributed article to ensure the privacy and secrecy of research is protected.

Authors should retain one copy of the text, tables, photographs and illustrations because rejected manuscripts will not be returned to the author(s) and the editors will not be responsible for loss or damage to photographs and illustrations sustained during mailing.

### **Online submissions**

Manuscripts should be submitted through the Online Submission System at: <http://www.wjgnet.com/1948-0210office>. Authors are highly recommended to consult the ONLINE INSTRUCTIONS TO AUTHORS ([http://www.wjgnet.com/1948-0210/g\\_info\\_20100313165700.htm](http://www.wjgnet.com/1948-0210/g_info_20100313165700.htm)) before attempting to submit online. For assistance, authors encountering problems with the Online Submission System may send an email describing the problem to [wjsc@wjgnet.com](mailto:wjsc@wjgnet.com), or by telephone: +86-10-85381891. If you submit your manuscript online, do not make a postal contribution. Repeated online submission for the same manuscript is strictly prohibited.

## MANUSCRIPT PREPARATION

All contributions should be written in English. All articles must be submitted using word-processing software. All submissions must be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Style should conform to our house format. Required information for each of the manuscript sections is as follows:

### **Title page**

**Title:** Title should be less than 12 words.

**Running title:** A short running title of less than 6 words should be provided.

**Authorship:** Authorship credit should be in accordance with the standard proposed by International Committee of Medical Journal Editors, based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.

**Institution:** Author names should be given first, then the complete name of institution, city, province and postcode. For example, Xu-

Chen Zhang, Li-Xin Mei, Department of Pathology, Chengde Medical College, Chengde 067000, Hebei Province, China. One author may be represented from two institutions, for example, George Sgourakis, Department of General, Visceral, and Transplantation Surgery, Essen 45122, Germany; George Sgourakis, 2nd Surgical Department, Korgialenio-Benakio Red Cross Hospital, Athens 15451, Greece

**Author contributions:** The format of this section should be: Author contributions: Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the paper.

**Supportive foundations:** The complete name and number of supportive foundations should be provided, e.g. Supported by National Natural Science Foundation of China, No. 30224801

**Correspondence to:** Only one corresponding address should be provided. Author names should be given first, then author title, affiliation, the complete name of institution, city, postcode, province, country, and email. All the letters in the email should be in lower case. A space interval should be inserted between country name and email address. For example, Montgomery Bissell, MD, Professor of Medicine, Chief, Liver Center, Gastroenterology Division, University of California, Box 0538, San Francisco, CA 94143, United States. montgomerybissell@ucsf.edu

**Telephone and fax:** Telephone and fax should consist of +, country number, district number and telephone or fax number, e.g. Telephone: +86-10-85381891 Fax: +86-10-85381893

**Peer reviewers:** All articles received are subject to peer review. Normally, three experts are invited for each article. Decision for acceptance is made only when at least two experts recommend an article for publication. Reviewers for accepted manuscripts are acknowledged in each manuscript, and reviewers of articles which were not accepted will be acknowledged at the end of each issue. To ensure the quality of the articles published in *WJSC*, reviewers of accepted manuscripts will be announced by publishing the name, title/position and institution of the reviewer in the footnote accompanying the printed article. For example, reviewers: Professor Jing-Yuan Fang, Shanghai Institute of Digestive Disease, Shanghai, Affiliated Renji Hospital, Medical Faculty, Shanghai Jiaotong University, Shanghai, China; Professor Xin-Wei Han, Department of Radiology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan Province, China; and Professor Anren Kuang, Department of Nuclear Medicine, Huaxi Hospital, Sichuan University, Chengdu, Sichuan Province, China.

### Abstract

There are unstructured abstracts (no more than 256 words) and structured abstracts (no more than 480). The specific requirements for structured abstracts are as follows:

An informative, structured abstracts of no more than 480 words should accompany each manuscript. Abstracts for original contributions should be structured into the following sections. AIM (no more than 20 words): Only the purpose should be included. Please write the aim as the form of "To investigate/study/..."; MATERIALS AND METHODS (no more than 140 words); RESULTS (no more than 294 words): You should present *P* values where appropriate and must provide relevant data to illustrate how they were obtained, e.g.  $6.92 \pm 3.86$  vs  $3.61 \pm 1.67$ ,  $P < 0.001$ ; CONCLUSION (no more than 26 words).

### Key words

Please list 5-10 key words, selected mainly from *Index Medicus*, which reflect the content of the study.

### Text

For articles of these sections, original articles and brief articles, the main text should be structured into the following sections: INTRODUCTION, MATERIALS AND METHODS, RESULTS and DISCUSSION, and should include appropriate Figures and Tables. Data should be presented in the main text or in Figures and Tables, but not in both. The main text format of these sections, editorial, topic highlight, case report, letters to the editors, can be found at: [http://www.wjgnet.com/1948-0210/g\\_info\\_list.htm](http://www.wjgnet.com/1948-0210/g_info_list.htm).

### Illustrations

Figures should be numbered as 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each figure on a separate page. Detailed legends should not be provided under the figures. This part should be added into the text where the figures are applicable. Figures should be either Photoshop or Illustrator files (in tiff, eps, jpeg formats) at high-resolution. Examples can be found at: <http://www.wjgnet.com/1007-9327/13/4520.pdf>; <http://www.wjgnet.com/1007-9327/13/4554.pdf>; <http://www.wjgnet.com/1007-9327/13/4891.pdf>; <http://www.wjgnet.com/1007-9327/13/4986.pdf>; <http://www.wjgnet.com/1007-9327/13/4498.pdf>. Keeping all elements compiled is necessary in line-art image. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend rather than on the bar itself. File names should identify the figure and panel. Avoid layering type directly over shaded or textured areas. Please use uniform legends for the same subjects. For example: Figure 1 Pathological changes in atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...*etc.* It is our principle to publish high resolution-figures for the printed and E-versions.

### Tables

Three-line tables should be numbered 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each table. Detailed legends should not be included under tables, but rather added into the text where applicable. The information should complement, but not duplicate the text. Use one horizontal line under the title, a second under column heads, and a third below the Table, above any footnotes. Vertical and italic lines should be omitted.

### Notes in tables and illustrations

Data that are not statistically significant should not be noted. <sup>a</sup>*P* < 0.05, <sup>b</sup>*P* < 0.01 should be noted (*P* > 0.05 should not be noted). If there are other series of *P* values, <sup>c</sup>*P* < 0.05 and <sup>d</sup>*P* < 0.01 are used. A third series of *P* values can be expressed as <sup>e</sup>*P* < 0.05 and <sup>f</sup>*P* < 0.01. Other notes in tables or under illustrations should be expressed as <sup>1</sup>F, <sup>2</sup>F, <sup>3</sup>F; or sometimes as other symbols with a superscript (Arabic numerals) in the upper left corner. In a multi-curve illustration, each curve should be labeled with ●, ○, ■, □, ▲, △, *etc.*, in a certain sequence.

### Acknowledgments

Brief acknowledgments of persons who have made genuine contributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.

## REFERENCES

### Coding system

The author should number the references in Arabic numerals according to the citation order in the text. Put reference numbers in square brackets in superscript at the end of citation content or after the cited author's name. For citation content which is part of the narration, the coding number and square brackets should be typeset normally. For example, "Crohn's disease (CD) is associated with increased intestinal permeability<sup>[1,2]</sup>". If references are cited directly in the text, they should be put together within the text, for example, "From references<sup>[19,22-24]</sup>, we know that..."

When the authors write the references, please ensure that the order in text is the same as in the references section, and also

## Instructions to authors

ensure the spelling accuracy of the first author's name. Do not list the same citation twice.

### PMID and DOI

Please provide PubMed citation numbers to the reference list, e.g. PMID and DOI, which can be found at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed> and <http://www.crossref.org/SimpleTextQuery/>, respectively. The numbers will be used in E-version of this journal.

### Style for journal references

Authors: the name of the first author should be typed in bold-faced letters. The family name of all authors should be typed with the initial letter capitalized, followed by their abbreviated first and middle initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). The title of the cited article and italicized journal title (journal title should be in its abbreviated form as shown in PubMed), publication date, volume number (in black), start page, and end page [PMID: 11819634 DOI: 10.3748/wjg.13.5396].

### Style for book references

Authors: the name of the first author should be typed in bold-faced letters. The surname of all authors should be typed with the initial letter capitalized, followed by their abbreviated middle and first initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR) Book title. Publication number. Publication place: Publication press, Year: start page and end page.

### Format

#### Journals

English journal article (list all authors and include the PMID where applicable)

- 1 **Jung EM**, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: A prospective controlled two-center study. *World J Gastroenterol* 2007; **13**: 6356-6364 [PMID: 18081224 DOI: 10.3748/wjg.13.6356]

Chinese journal article (list all authors and include the PMID where applicable)

- 2 **Lin GZ**, Wang XZ, Wang P, Lin J, Yang FD. Immunologic effect of Jianpi Yishen decoction in treatment of Pixu-diarhoea. *Shijie Huaren Xiaobua Zazhi* 1999; **7**: 285-287

In press

- 3 **Tian D**, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in Arabidopsis. *Proc Natl Acad Sci USA* 2006; In press

Organization as author

- 4 **Diabetes Prevention Program Research Group**. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; **40**: 679-686 [PMID: 12411462 PMID:2516377 DOI:10.1161/01.HYP.0000035706.28494.09]

Both personal authors and an organization as author

- 5 **Vallancien G**, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. *J Urol* 2003; **169**: 2257-2261 [PMID: 12771764 DOI:10.1097/01.ju.0000067940.76090.73]

No author given

- 6 21st century heart solution may have a sting in the tail. *BMJ* 2002; **325**: 184 [PMID: 12142303 DOI:10.1136/bmj.325.7357.184]

Volume with supplement

- 7 **Geraud G**, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002; **42** Suppl 2: S93-99 [PMID: 12028325 DOI:10.1046/j.1526-4610.42.s2.7.x]

Issue with no volume

- 8 **Banit DM**, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. *Clin Orthop Relat Res* 2002; (**401**): 230-238 [PMID: 12151900 DOI:10.1097/00003086-200208000-00026]

No volume or issue

- 9 Outreach: Bringing HIV-positive individuals into care. *HRS-A Careaction* 2002; 1-6 [PMID: 12154804]

### Books

Personal author(s)

- 10 **Sherlock S**, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Sci Pub, 1993: 258-296

Chapter in a book (list all authors)

- 11 **Lam SK**. Academic investigator's perspectives of medical treatment for peptic ulcer. In: Swabb EA, Azabo S. Ulcer disease: investigation and basis for therapy. New York: Marcel Dekker, 1991: 431-450

Author(s) and editor(s)

- 12 **Breedlove GK**, Schorfheide AM. Adolescent pregnancy. 2nd ed. Wicczorek RR, editor. White Plains (NY): March of Dimes Education Services, 2001: 20-34

Conference proceedings

- 13 **Harnden P**, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ cell tumours Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer, 2002: 30-56

Conference paper

- 14 **Christensen S**, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer, 2002: 182-191

Electronic journal (list all authors)

- 15 Morse SS. Factors in the emergence of infectious diseases. *Emerg Infect Dis* serial online, 1995-01-03, cited 1996-06-05; 1(1): 24 screens. Available from: URL: <http://www.cdc.gov/ncidod/eid/index.htm>

Patent (list all authors)

- 16 **Pagedas AC**, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1

### Statistical data

Write as mean  $\pm$  SD or mean  $\pm$  SE.

### Statistical expression

Express *t* test as *t* (in italics), *F* test as *F* (in italics), chi square test as  $\chi^2$  (in Greek), related coefficient as *r* (in italics), degree of freedom as  $\nu$  (in Greek), sample number as *n* (in italics), and probability as *P* (in italics).

### Units

Use SI units. For example: body mass, *m* (B) = 78 kg; blood pressure, *p* (B) = 16.2/12.3 kPa; incubation time, *t* (incubation) = 96 h, blood glucose concentration, *c* (glucose) 6.4  $\pm$  2.1 mmol/L; blood CEA mass concentration, *p* (CEA) = 8.6 24.5  $\mu$ g/L; CO<sub>2</sub> volume fraction, 50 mL/L CO<sub>2</sub>, not 5% CO<sub>2</sub>; likewise for 40 g/L formaldehyde, not 10% formalin; and mass fraction, 8 ng/g, etc. Arabic numerals such as 23, 243, 641 should be read 23 243 641.

The format for how to accurately write common units and quantum numbers can be found at: [http://www.wjnet.com/1948-0210/g\\_info\\_20100313172144.htm](http://www.wjnet.com/1948-0210/g_info_20100313172144.htm).

### Abbreviations

Standard abbreviations should be defined in the abstract and on first mention in the text. In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Permissible abbreviations are listed in Units, Symbols and Abbreviations: A Guide for Biological and Medical Editors and

Authors (Ed. Baron DN, 1988) published by The Royal Society of Medicine, London. Certain commonly used abbreviations, such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, mAb, can be used directly without further explanation.

### Italics

Quantities: *t* time or temperature, *c* concentration, *A* area, *l* length, *m* mass, *V* volume.

Genotypes: *gyrA*, *arg 1*, *c myc*, *c fos*, etc.

Restriction enzymes: *EcoRI*, *HindIII*, *BamHI*, *Kho I*, *Kpn I*, etc.

Biology: *H. pylori*, *E. coli*, etc.

### Examples for paper writing

**Editorial:** [http://www.wjgnet.com/1948-0210/g\\_info\\_20100313165833.htm](http://www.wjgnet.com/1948-0210/g_info_20100313165833.htm)

**Frontier:** [http://www.wjgnet.com/1948-0210/g\\_info\\_20100313170509.htm](http://www.wjgnet.com/1948-0210/g_info_20100313170509.htm)

**Topic highlight:** [http://www.wjgnet.com/1948-0210/g\\_info\\_20100313170618.htm](http://www.wjgnet.com/1948-0210/g_info_20100313170618.htm)

**Observation:** [http://www.wjgnet.com/1948-0210/g\\_info\\_20100313170727.htm](http://www.wjgnet.com/1948-0210/g_info_20100313170727.htm)

**Guidelines for basic research:** [http://www.wjgnet.com/1948-0210/g\\_info\\_20100313170855.htm](http://www.wjgnet.com/1948-0210/g_info_20100313170855.htm)

**Guidelines for clinical practice:** [http://www.wjgnet.com/1948-0210/g\\_info\\_20100313171012.htm](http://www.wjgnet.com/1948-0210/g_info_20100313171012.htm)

**Review:** [http://www.wjgnet.com/1948-0210/g\\_info\\_20100313171124.htm](http://www.wjgnet.com/1948-0210/g_info_20100313171124.htm)

**Original articles:** [http://www.wjgnet.com/1948-0210/g\\_info\\_20100313171239.htm](http://www.wjgnet.com/1948-0210/g_info_20100313171239.htm)

**Brief articles:** [http://www.wjgnet.com/1948-0210/g\\_info\\_20100313171358.htm](http://www.wjgnet.com/1948-0210/g_info_20100313171358.htm)

**Case report:** [http://www.wjgnet.com/1948-0210/g\\_info\\_20100313171504.htm](http://www.wjgnet.com/1948-0210/g_info_20100313171504.htm)

**Letters to the editor:** [http://www.wjgnet.com/1948-0210/g\\_info\\_20100313171613.htm](http://www.wjgnet.com/1948-0210/g_info_20100313171613.htm)

**Book reviews:** [http://www.wjgnet.com/1948-0210/g\\_info\\_20100313171713.htm](http://www.wjgnet.com/1948-0210/g_info_20100313171713.htm)

**Guidelines:** [http://www.wjgnet.com/1948-0210/g\\_info\\_20100313171803.htm](http://www.wjgnet.com/1948-0210/g_info_20100313171803.htm)

## SUBMISSION OF THE REVISED MANUSCRIPTS AFTER ACCEPTED

Please revise your article according to the revision policies of *WJSC*. The revised version including manuscript and high-resolution image figures (if any) should be copied on a floppy or compact disk. The author should send the revised manuscript, along with printed high-resolution color or black and white photos,

copyright transfer letter, and responses to the reviewers by courier (such as EMS/DHL).

### Editorial Office

#### *World Journal of Stem Cells*

Editorial Department: Room 903, Building D, Ocean International Center, No. 62 Dongsihuan Zhonglu, Chaoyang District, Beijing 100025, China

E-mail: [wjsc@wjgnet.com](mailto:wjsc@wjgnet.com)

<http://www.wjgnet.com>

Telephone: +86-10-8538-1891

Fax: +86-10-8538-1893

### Language evaluation

The language of a manuscript will be graded before it is sent for revision. (1) Grade A: priority publishing; (2) Grade B: minor language polishing; (3) Grade C: a great deal of language polishing needed; and (4) Grade D: rejected. Revised articles should reach Grade A or B.

### Copyright assignment form

Please download a Copyright assignment form from [http://www.wjgnet.com/1948-0210/g\\_info\\_20100313172045.htm](http://www.wjgnet.com/1948-0210/g_info_20100313172045.htm).

### Responses to reviewers

Please revise your article according to the comments/suggestions provided by the reviewers. The format for responses to the reviewers' comments can be found at: [http://www.wjgnet.com/1948-0210/g\\_info\\_20100313172000.htm](http://www.wjgnet.com/1948-0210/g_info_20100313172000.htm).

### Proof of financial support

For paper supported by a foundation, authors should provide a copy of the document and serial number of the foundation.

### Links to documents related to the manuscript

*WJSC* will be initiating a platform to promote dynamic interactions between the editors, peer reviewers, readers and authors. After a manuscript is published online, links to the PDF version of the submitted manuscript, the peer-reviewers' report and the revised manuscript will be put on-line. Readers can make comments on the peer reviewer's report, authors' responses to peer reviewers, and the revised manuscript. We hope that authors will benefit from this feedback and be able to revise the manuscript accordingly in a timely manner.

### Science news releases

Authors of accepted manuscripts are suggested to write a science news item to promote their articles. The news will be released rapidly at EurekAlert/AAAS (<http://www.eurekalert.org>). The title for news items should be less than 90 characters; the summary should be less than 75 words; and main body less than 500 words. Science news items should be lawful, ethical, and strictly based on your original content with an attractive title and interesting pictures.

### Publication fee

*WJSC* is an international, peer-reviewed, Open-Access, online journal. Articles published by this journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. Authors of accepted articles must pay a publication fee. The related standards are as follows. Publication fee: 1300 USD per article. Editorial, topic highlights, book reviews and letters to the editor are published free of charge.